PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsAids-related opportunistic infections
MeSH D017088 - aids-related opportunistic infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009894:Opportunistic infections
0 Companies
0 Drugs
Success rate
D015658:Hiv infections
45 Companies
41 Drugs
$
Success rate
D017088: 
Aids-related opportunistic infections
118 Companies
23 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AbbVieAcyclovir Acyclovir  1999-07-26   
Sulfadiazine Sulfadiazine  1982-01-01   
Dapsone Aczone  2005-07-07   
Able LaboratoriesPhenazopyridine, Sulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim Phenazopyridine  2001-06-26   
Alembic PharmaceuticalsAcyclovir Acyclovir  2018-04-06   
Dapsone Dapsone  2023-10-27   
Allegis PharmaceuticalsTrimethoprim Primsol  1995-06-23   
AllerganTrimethoprim, Polymyxin b Polytrim  1988-10-20   
Acyclovir Acyclovir  1997-04-28   
Dapsone Dapsone  2017-03-23   
Rifampin Rifampin  2016-01-19   
Sulfamethoxazole, Trimethoprim Sulfamethoxazole Trimethoprim  1984-11-07   
Trimethoprim Trimethoprim  1985-06-06   
1
2
3
4
5
6
...
12
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
0%
0/0
Phase 3
94%
16/17
Approved: 15Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Allergan
Dapsone
Almirall
Dapsone
1
2
3
4
5
6
...
8
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use